Can dopamine prevent the renal side effects of indomethacin?: A prospective randomized clinical study;Kann dopamin die renalen nebenwirkungen von indometacin verhindern?

Klinische Padiatrie

Volumn 211, Issue 6, 1999, Pages 438-441

  Baenziger, Oskar ^a   Waldvogel, Katharina ^b   Ghelfi, Daniela ^b   Arbenz, Urs ^b   Fanconi, Sergio ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b NONE

Author keywords

Dopamine; Indomethacin; Neonates; Patent ductus arteriosus; Preterm infants

Indexed keywords

DOPAMINE; INDOMETACIN;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEWBORN; PATENT DUCTUS ARTERIOSUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SODIUM EXCRETION;

EID: 0032695477     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043829     Document Type: Review

References (26)

1. 1 Clyman, R. I.: Indomethacin therapy for patent ductus arteriosus: when is prophylaxis not prophylactic? J. Pediatr. 111 (1987) 718-721
2. 2 Cuevas, L., T. F. Yeh, D. Cuevas, R. S. Plides: The effect of low-dose dopamine infusion on cardiopulmonary and renal status in premature newborns with respiratory distress syndrome. AJDC 145 (1991) 799-803
3. 3 Fajardo, C. A., R. K. Whyte, B. T. Steet: Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus. J. Pediatr. 121 (1992) 771-775
4. 4 Friedman, Z., L. M. Demers, K. H. Marks, S. Uhrmann, M. J. Maisels: Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants. J. Pediatr. 93 (1978) 512-515
5. 5 Gersony, W. M., G. J. Peckham, R. C. Ellison, O. S. Miettinen, A. S. Nadas: Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J. Pediatr. 102 (1983) 895-906
6. 6 Green, T. P., T. R. Thompson, D. Johnson, J. E. Lock: Furosemide use in premature infants and appearance of patent ductus arteriosus. Am. J. Dis. Child. 135 (1981) 239-243
7. 7 Girardin, E., M. Berner, J. C. Rouge, R. V. Rivest, B. Friedli, L. Paunier: Effect of low dose dopamine on haemodynamic and renal function in children. Pediatr. Res. 26 (1989) 200-203
8. 8 Green, T. P., T. R. Thompson, D. Johnson, J. E. Lock: Furosemide promotes patent ductus arteriosus in premature infants with the respirato-ry-distress syndrome. N. Engl. J. Med. 308 (1983) 743-748
9. 9 Hammerman, C., M. J. Aramburo: Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J. Pediatr. 117 (1990) 771-776
10. 10 John, E. G., U. Vasan, A. R. Hastreiter, R. Bhat, M. A. Evans: Intravenous indomethacin and changes of renal function in premature infants with patent ductus arteriosus. J. Pediatr. 96 (1984) 737-739
11. 11 Manoogian, C., J. Nadler, L. Ehrlich, R. Horton: The renal vasodilating effect of dopamine is mediated by calcium flux and prostacyclin release in man. J. Clin. Endocrinol. Metab. 66 (1988) 678-683
12. 12 Mardoum, R., R. Bejar, A. Merritt, C. Berry: Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants. J. Pediatr. 118 (1991) 112-115
13. 13 McDonald, R. H., L. I. Goldberg, J. L. McNay, E. P. Tuttle: Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J. Clin. Invest. 43 (1964) 1116-1124
14. 14 Meyers, R. L., G. Alpan, E. Lin, R. L. Clyman: Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxigen consumption. Pediatr. Res. 29 (1991) 569-574
15. 15 Miall-Allen, V. M., A. G. L. Whitelaw: Response to dopamine and dobutamine in the preterm infant less than 30 weeks gestation. Crit. Care Med. 17 (1989) 1166-1169
16. 16 Padbury, J. F.: Neonatal dopamine pharmacodynamics: lessons from the bedside. J. Pediatr. 133 (1998) 719-720
17. 17 Palak, R. V., S. Z. Fadem, S. G. Rosenblatt, M. D. Lifschitz, J. H. Stein: Diuretic-induced changes in renal blood flow and prostaglandin E excretion in dog. Am. J. Physiol. 236 (1979) F494-500
18. 18 Peckham, G. J., O. S. Mieuinen, R. Ellison, E. N. Kraybill, W. M. Gersony, S. Zierlaer, A. Nadas: Clinical course of 1 year of age in premature infants with patent ductus arteriosus: results of a multicentre randomized trial of indomethacin. J. Pediatr. 105 (1984) 288-291
19. 19 Pelayo, J. C., R. D. Fildes, P. A. Jose: Age dependent renal effects on intrarenal dopamine infusion Am. J. Physiol. 247 (1984) R212-216
20. 20 Seri, I., T. Tulassay, J. Kiszel, S. Csomor: The use of dopamine for the prevention of the renal side effects of indomethacin in premature infants with patent ductus arteriosus. Int. J. Ped. Nephrol. 5 (1984) 209-214
21. 21 Seri, I.: Effect of dopamine on indomethacin-induced impairement of renal function in preterm neonates. J. Pediatr. 123 (1993) 169
22. 22 Seri, I., S. Abbasi, D. C Wood, J. S. Gerdes: Regional hemodynamic effects of dopamine in the sick preterm neonate. J. Pediatr. 133 (1998) 728-734
23. 23 Tulassay, T., I. Seri: Acute oliguria in preterm infants with hyaline membrane: interaction of dopamine and furosemide. Acta Paediatr. Scand. 75 (1986) 420-424
24. 24 Yeh, T. F., A. Wilks, J. Singh, M. V. Betrekur, Lilien, R. S. Pildes: Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus. J. Pediatr. 101 (1982) 433-437
25. 25 Van den Anker, J. N.: Pharmacokinetics and renal function in preterm infants. Acta Paediatr. 85 (1996) 1393-1399
26. 26 Walters, M.: Tolerance of intravenous indomethacin treatment for premature infants with patent ductus arteriosus. BMJ 297 (1988) 773-774